Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company based in Utah that develops, manufactures, and markets advanced diagnostic technologies [4] - The company's technologies focus on tests designed for the detection and analysis of nucleic acid molecules (DNA or RNA) [4] - Co-Diagnostics utilizes proprietary technology to create specific tests for its Co-Dx PCR platform, which includes at-home and point-of-care testing [4] Conference Participation - Co-Diagnostics will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City [1] - The conference aims to connect emerging growth issuers across various sectors with institutional investors [2] - Company representatives will engage in one-on-one meetings to present the company's value proposition and the upcoming Co-Dx PCR testing platform [2] Product Information - The Co-Dx PCR platform includes the PCR Home™, PCR Pro™, a mobile app, and associated tests [3] - The platform is currently under review by the FDA and other regulatory bodies and is not yet available for sale [3]